Clinical TrialsIFx-2.0 demonstrated substantial responses in patients who progressed on multiple checkpoint therapies, leading to positive FDA feedback and an SPA agreement for a Phase 3 trial.
Financial OutlookTuHURA Biosciences ended the year with cash, cash equivalents, and marketable securities of approximately $12.7 million, which should be sufficient to fund operations into the fourth quarter of 2025.
Strategic PartnershipsUpcoming catalysts include the completion of a merger with Kineta, Inc., which provides full rights to Kineta's novel VISTA-targeted mAb.